• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

ACADIA Pharmaceuticals (ACAD)

Common Shares
Sell: $21.00|Buy: $23.00|Change: 0.06 (0.27%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Address

3611 Valley Centre Drive
Suite 300
San Diego
CA
USA
92130

Telephone

+1 858 558-2871

Website

https://www.acadia.com

Sector 

Healthcare

Forecast key dates

NameKey Date
ACADIA Pharmaceuticals Inc Annual Report for 20262027-02-26T00:00:00
ACADIA Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20262027-02-25T16:30:00
ACADIA Pharmaceuticals Inc Fourth Quarter Earnings Results for 20262027-02-25T00:00:00
ACADIA Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20262026-11-05T16:30:00
ACADIA Pharmaceuticals Inc Third Quarter Earnings Results for 20262026-11-05T00:00:00
ACADIA Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20262026-08-06T16:30:00
ACADIA Pharmaceuticals Inc Second Quarter Earnings Results for 20262026-08-06T00:00:00
ACADIA Pharmaceuticals Inc Annual General Meeting for 20262026-05-29T08:00:00
ACADIA Pharmaceuticals Inc First Quarter Earnings Conference Call for 20262026-05-07T16:30:00
ACADIA Pharmaceuticals Inc First Quarter Earnings Results for 20262026-05-07T00:00:00

Previous key dates

NameKey Date
Stifel 2026 Virtual CNS Forum2026-03-17T08:00:00
ACADIA Pharmaceuticals Inc Annual Report for 20252026-02-26T00:00:00
ACADIA Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20252026-02-25T16:30:00
ACADIA Pharmaceuticals Inc Fourth Quarter Earnings Results for 20252026-02-25T00:00:00
44th Annual J.P. Morgan Healthcare Conference2026-01-13T12:45:00
Citi’s 2025 Global Healthcare Conference2025-12-02T09:45:00
Jefferies Global Healthcare Conference2025-11-18T08:30:00
UBS Global Healthcare Conference2025-11-10T14:00:00
ACADIA Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20252025-11-05T16:30:00
ACADIA Pharmaceuticals Inc Third Quarter Earnings Result for 20252025-11-05T00:00:00
TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit2025-09-18T13:40:00
H.C. Wainwright 27th Annual Global Investment Conference2025-09-09T08:00:00
Morgan Stanley 23rd Annual Global Healthcare Conference2025-09-08T10:45:00
ACADIA Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20252025-08-06T16:30:00
ACADIA Pharmaceuticals Inc Second Quarter Earnings Results for 20252025-08-06T00:00:00
R&D Day 20252025-06-25T08:30:00
Goldman Sachs 46th Annual Global Healthcare Conference2025-06-09T16:00:00
ACADIA Pharmaceuticals Inc Annual General Meeting for 20252025-05-29T08:00:00
BofA Securities 2025 Health Care Conference2025-05-13T15:40:00
ACADIA Pharmaceuticals Inc First Quarter Earnings Conference Call for 20252025-05-07T16:30:00
ACADIA Pharmaceuticals Inc First Quarter Earnings Results for 20252025-05-07T00:00:00
24th Annual Needham Virtual Healthcare Conference2025-04-07T10:15:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.